First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

Area of Science:

• Oncology
• Clinical Trials
• Immunotherapy

Background:

• Extensive-stage small cell lung cancer (ES-SCLC) is aggressive with limited treatment options.
• Chemo-immunotherapy is a new standard treatment for ES-SCLC.
• Real-world data is needed for patient subgroups excluded from clinical trials.

Purpose of the Study:

• To evaluate the real-world effectiveness of chemo-immunotherapy in ES-SCLC patients.
• To assess outcomes in patient subpopulations not eligible for pivotal trials.

Main Methods:

• Retrospective binational multicenter study.
• Included 436 patients with ES-SCLC treated with platinum-etoposide and immunotherapy.
• Analyzed overall survival (OS), progression-free survival, response rates, and safety.

Main Results:

• 32.6% of patients were ineligible for pivotal trials.
• Median OS was 9.3 months; 2-year OS was 14%.
• Outcomes were similar to registrational trials, with comparable safety profiles.

Conclusions:

• This is the largest real-world cohort for ES-SCLC chemo-immunotherapy.
• Survival and safety data support chemo-immunotherapy as first-line treatment.
• Chemo-immunotherapy is effective in routine clinical practice for ES-SCLC.